Feed GXI.DE
GX

Gerresheimer

GXI.DE · XETRA

27.60 € +5.99% (+1.56 €)
1M -7.40%
Market Cap 895.3M €
P/E Ratio -
Div. Yield -
ROE 23.57%

Bulios Fair Price

17.77 €

35.6% downside

Current Price

27.6 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, GXI.DE is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
2/9
Valuation
98 /100
Cheap
P/B 0.83x
EV/EBITDA 7.41x
P/S 0.39x
Growth
64 /100
Stable
Book val. growth 15.49%
EPS growth 6.00%
Rev. growth 10.77%
Profitability
5 /100
Weak
Op. margin 9.02%
Gross margin 18.32%
FCF margin 4.26%
Quality
6 /100
Poor
ROA 7.13%
ROIC 7.05%
Asset turnover 0.52x
Debt
20 /100
High
Int. coverage -2.34x
Debt/Equity 1.48x
Net debt/EBITDA 4.55x
Stability
87 /100
Stable
EPS volatility 13.16%
Beta 0.48x
Profitable years 4

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about GXI.DE
Online

About the company

Gerresheimer AG (GXI) is a German multinational company specializing in the production and supply of specialty glass and plastics primarily for the pharmaceutical industry. With a broad range of products, such as injection vials, ampoules, and pharmacy containers, Gerresheimer AG is a key player in the pharmaceutical supply chain. The company is known for its innovative technology and high-quality standards, making it a preferred partner for pharmaceutical companies worldwide. Gerresheimer AG (GXI) could be an attractive investment opportunity for investors seeking stability and growth potential in the pharmaceutical supply sector.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Uwe Ferdinand Röhrhoff

Employees

13,528

Headquarters

Düsseldorf

Upcoming events

29 SEP

Earnings

Upcoming earnings report

1d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.